Bayer says 2024 sales of prostate cancer drug above $1 bln

Bayer (BAYGn.DE) on Thursday predicted at least $1 billion in 2024 sales for prostate cancer drug Nubeqa, which is playing a bigger role for the drugmaker's growth prospects after the failure of a promising anti-blood-clotting therapy.